出版社：Centre for Innovation Law and Policy at the University of Toronto, Faculty of Law
摘要：In the midst of many glorifying announcements
of major breakthroughs in medical research,
arguments for caution, regulatory control and
restraint are often lost or brushed aside as the
whining of doom thinkers. Canada, as other
industrialized countries, has embraced new
biotechnology, characterized by strong alliances
between governmental funding agencies, industry,
academic researchers and health care
providers. This development comes, however, at
a price; and it requires an appropriate regulatory
response.
